Closely-held Cytel, a global leader in clinical trial design and software, announced today its strategic partnership with OneMedNet (NASDAQ:ONMD) to enhance data-driven healthcare solutions.
The partnership will integrate OneMedNet’s robust clinical and extensive imaging Real World Data platform for over 121 million clinical exams from over 1,400 U.S. locations with Cytel’s advanced analytics capabilities. This synergy will enable customers in the biotech and pharma sectors to access ONMD’s data via Cytel’s Fit For Purpose Data Tool, fostering innovation in trial design, observational studies, and development of AI/ML models. The combined clinical and imaging data is specifically tailored to meet the analytics needs of sponsors across multiple therapeutic areas including neurologic disorders, oncology, and cardiology.
In a statement, Massoud Toussi, Cytel’s Vice President, Global Head of Real-World Evidence, said “As a human data science company, we’re thrilled to announce our strategic partnership with OneMedNet. Their unique access to data from imaging devices, combined with their innovative iRWD platform for collecting additional clinical data, aligns perfectly with our mission. This collaboration will empower us to deliver additional valuable solutions to our clients and drive meaningful impact in our industry.”
In June, OneMedNet announced an alliance with a “clinical trial design and software global leader,” but did not reveal the new partner’s name. BioTuesdays has now confirmed that it was Cytel.
At the time of OneMedNet’s announcement, Aaron Green, the company’s president and CEO, said that the partnership aligned perfectly with OneMedNet’s market expansion strategy and significantly extends its commercial reach within the global science industry. “Our new partner’s recognized expertise in clinical trial design and implementation, combined with our innovative RWD platform, creates a powerful synergy that should help accelerate the development of innovative new medical therapies and technologies targeting some of the world’s greatest health challenges.”
